药物发现
药物开发
药品
药物重新定位
重新调整用途
计算机科学
数据科学
业务
医学
药理学
工程类
生物信息学
生物
废物管理
作者
Jeffrey W. Strovel,Sitta Sittampalam,Nathan P. Coussens,Michael Hughes,James Inglese,Andrew Kurtz,Ali Andalibi,Lavonne Patton,Chris P. Austin,Michael Jay Baltezor,Michael Beckloff,Michael Weingarten,Scott James Weir
摘要
Setting up drug discovery and development programs in academic, non-profit and other life science research companies requires careful planning. This chapter contains guidelines to develop therapeutic hypotheses, target and pathway validation, proof of concept criteria and generalized cost analyses at various stages of early drug discovery. Various decision points in developing a New Chemical Entity (NCE), description of the exploratory Investigational New Drug (IND) and orphan drug designation, drug repurposing and drug delivery technologies are also described and geared toward those who intend to develop new drug discovery and development programs.Note: The estimates and discussions below are modeled for an oncology drug New Molecular Entity (NME) and repurposed drugs. For other disease indications these estimates might be significantly higher or lower.
科研通智能强力驱动
Strongly Powered by AbleSci AI